{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:07:47Z","timestamp":1792681667161,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ctrv.2014.05.010","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T23:45:13Z","timestamp":1402098313000},"page":"900-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Primary breast lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Chan Y.","family":"Cheah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.05.010_b0005","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1093\/annonc\/mdt192","article-title":"Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options","volume":"24","author":"Aviv","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clbc.2012.07.006","article-title":"Treatment and outcomes of primary breast lymphoma","volume":"12","author":"Caon","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1186\/1471-2407-8-86","article-title":"Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study","volume":"8","author":"Jeanneret-Sozzi","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdm471","article-title":"Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group","volume":"19","author":"Ryan","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0025","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1097\/PAS.0b013e318165eb50","article-title":"Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms","volume":"32","author":"Talwalkar","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0030","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1259\/bjr\/78413721","article-title":"Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features","volume":"85","author":"Surov","year":"2012","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00000478-199403000-00009","article-title":"Non-Hodgkin\u2019s lymphoma involving the breast","volume":"18","author":"Arber","year":"1994","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2325\/jbcs.12.154","article-title":"Primary non-Hodgkin\u2019s lymphoma of the breast: report of a case with special reference to 380 cases in the Japanese literature","volume":"12","author":"Uesato","year":"2005","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.21353","article-title":"Primary breast non-Hodgkin\u2019s lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors","volume":"84","author":"Validire","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/1471-2407-10-321","article-title":"Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study","volume":"10","author":"Yhim","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0055","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/1097-0142(197206)29:6<1705::AID-CNCR2820290640>3.0.CO;2-I","article-title":"Primary lymphoma of the breast","volume":"29","author":"Wiseman","year":"1972","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0060","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/1097-0142(19901215)66:12<2602::AID-CNCR2820661224>3.0.CO;2-U","article-title":"Primary breast lymphoma. An immunohistologic study of 20 new cases","volume":"66","author":"Hugh","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0065","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.anndiagpath.2012.01.004","article-title":"Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype","volume":"16","author":"Li","year":"2012","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4174\/jkss.2013.84.5.267","article-title":"Primary breast lymphoma: a single institution\u2019s experience","volume":"84","author":"Jung","year":"2013","journal-title":"J Korean Surg Soc"},{"key":"10.1016\/j.ctrv.2014.05.010_b0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1099-1069(199702)15:1<33::AID-HON595>3.0.CO;2-K","article-title":"Lymphoma of the breast in Hong Kong Chinese","volume":"15","author":"Au","year":"1997","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0080","doi-asserted-by":"crossref","DOI":"10.3322\/caac.21173","article-title":"Breast cancer statistics, 2013","author":"Desantis","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2014.05.010_b0085","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4048\/jbc.2011.14.4.333","article-title":"A rare case of male primary breast lymphoma","volume":"14","author":"Rathod","year":"2011","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0090","article-title":"Primary breast lymphoma: 30 years of experience with diagnosis and treatment at a single medical center","author":"Radkani","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ctrv.2014.05.010_b0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jso.10084","article-title":"Primary non-Hodgkin lymphoma of the breast: the Mayo Clinic experience","volume":"80","author":"Wong","year":"2002","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0100","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.breast.2003.11.002","article-title":"Primary breast lymphoma in a male patient","volume":"13","author":"Mpallas","year":"2004","journal-title":"The Breast"},{"key":"10.1016\/j.ctrv.2014.05.010_b0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/oxfordjournals.jjco.a023222","article-title":"Primary non-Hodgkin malignant lymphoma of the male breast","volume":"26","author":"Murata","year":"1996","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjh.12753","article-title":"A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era","volume":"165","author":"Hosein","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00000658-198702000-00008","article-title":"Malignant lymphoma of the breast. A study of 53 patients","volume":"205","author":"Brustein","year":"1987","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2014.05.010_b0120","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1046\/j.1524-4741.2002.08509.x","article-title":"Lymphoma of the breast: clinical and radiologic features with pathologic correlation in 28 patients","volume":"8","author":"Sabat\u00e9","year":"2002","journal-title":"Breast J"},{"key":"10.1016\/j.ctrv.2014.05.010_b0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22753","article-title":"Non-Hodgkin lymphoma of the breast","volume":"110","author":"Ganjoo","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0130","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2012-04-423095","article-title":"Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination","volume":"120","author":"Benevolo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.05.010_b0135","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1600-0609.2011.01679.x","article-title":"Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution","volume":"87","author":"Fukuhara","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s12185-008-0085-4","article-title":"Primary non-Hodgkin\u2019s lymphoma of the breast: eight-year follow-up experience","volume":"87","author":"Guo","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.21522","article-title":"Uncertainty and discordance in the staging and prognosis of diffuse large B-cell lymphoma with isolated bilateral testicular involvement","volume":"84","author":"Go","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin\u2019s lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.05.010_b0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-005-5088-8","article-title":"High grade primary breast lymphoma: is it a different clinical entity?","volume":"93","author":"Fruchart","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.05.010_b0160","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.leukres.2008.04.005","article-title":"Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma","volume":"32","author":"Niitsu","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.ctrv.2014.05.010_b0165","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/sj.bjc.6603123","article-title":"Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin\u2019s lymphoma: a Danish population-based cohort study","volume":"94","author":"Norgaard","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0170","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s10552-010-9626-2","article-title":"Reproductive factors, menopausal hormone therapy, and risk of non-Hodgkin, diffuse large B-cell and follicular lymphomas: a UK case-control study","volume":"21","author":"Mildon","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ctrv.2014.05.010_b0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ijc.11083","article-title":"Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies","volume":"105","author":"Fernandez","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0180","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3109\/10428194.2012.722216","article-title":"Postmenopausal unopposed estrogen and estrogen plus progestin use and risk of non-Hodgkin lymphoma in the American Cancer Society Cancer Prevention Study-II Cohort","volume":"54","author":"Teras","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2014.05.010_b0185","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00026.2006","article-title":"Estrogen receptors: how do they signal and what are their targets","volume":"87","author":"Heldring","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ctrv.2014.05.010_b0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1210\/endo.138.3.4979","article-title":"Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta","volume":"138","author":"Kuiper","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2014.05.010_b0195","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/path.1883","article-title":"Differential expression of oestrogen receptors in human secondary lymphoid tissues","volume":"208","author":"Shim","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2013.05.016","article-title":"Estrogen receptor \u03b1 and \u03b2 in the normal immune system and in lymphoid malignancies","author":"Yakimchuk","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0205","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2011.68","article-title":"Effect of ligand-activated estrogen receptor \u03b2 on lymphoma growth in vitro and in vivo","volume":"25","author":"Yakimchuk","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2014.05.010_b0210","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood-2013-07-517292","article-title":"Inhibition of lymphoma vascularization and dissemination by estrogen receptor beta agonists","volume":"123","author":"Yakimchuk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.05.010_b0215","first-page":"85","article-title":"Breast lymphoma. A clinical and pathological review and 10-year treatment results","volume":"85","author":"Ariad","year":"1995","journal-title":"S Afr Med J"},{"key":"10.1016\/j.ctrv.2014.05.010_b0220","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0046-8177(93)90037-H","article-title":"Breast lymphomas: a clinicopathologic review","volume":"24","author":"Bobrow","year":"1993","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0225","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/bjc.1988.314","article-title":"Histiocytic lymphoma of breast responds to tamoxifen","volume":"58","author":"Millis","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1477-7819-8-53","article-title":"Primary breast lymphomas: a multicentric experience","volume":"8","author":"Avenia","year":"2010","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0235","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cncr.10163","article-title":"Lymphomas of the breast: primary and secondary involvement","volume":"94","author":"Domchek","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0240","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.semdp.2012.08.005","article-title":"Immunosuppressive and immunomodulatory therapy-associated lymphoproliferative disorders","volume":"30","author":"Bagg","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0245","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/j.lpm.2012.05.025","article-title":"Predictors for the development of non-Hodgkin lymphoma in primary Sjogren\u2019s syndrome","volume":"41","author":"Jonsson","year":"2012","journal-title":"Presse Med"},{"key":"10.1016\/j.ctrv.2014.05.010_b0250","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01.sla.0000254418.90192.59","article-title":"Primary breast lymphoma: the role of mastectomy and the importance of lymph node status","volume":"245","author":"Jennings","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2014.05.010_b0255","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/annonc\/mdp238","article-title":"Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group","volume":"20","author":"Martinelli","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0260","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF03256380","article-title":"Primary bilateral Burkitt lymphoma of the lactating breast: a case report and review of the literature","volume":"14","author":"Negahban","year":"2010","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.ctrv.2014.05.010_b0265","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000317344","article-title":"Burkitt\u2019s lymphoma in pregnancy with bilateral breast involvement: case report with review of the literature","volume":"33","author":"Savvari","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.ctrv.2014.05.010_b0270","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAI.0b013e318195286d","article-title":"Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases","volume":"17","author":"Gualco","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0280","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3109\/0284186X.2011.602116","article-title":"A rare occurrence of primary T-cell lymphoma of the breast in pregnancy","volume":"50","author":"Ozkan","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0285","first-page":"163","article-title":"Et al.","volume":"30","author":"Boullanger","year":"2001","journal-title":"Presse Med"},{"key":"10.1016\/j.ctrv.2014.05.010_b0290","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1524-4741.2008.00581.x","article-title":"Mantle cell lymphoma with bilateral palpable breast masses","volume":"14","author":"Hill","year":"2008","journal-title":"Breast J"},{"key":"10.1016\/j.ctrv.2014.05.010_b0295","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jcp.54.11.883","article-title":"Mantle cell lymphoma presenting as a breast mass","volume":"54","author":"Windrum","year":"2001","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","author":"Rummel","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.ctrv.2014.05.010_b0305","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","article-title":"Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study","volume":"91","author":"Kang","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0310","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.2011.40.6272","article-title":"Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study","volume":"31","author":"Zucca","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0315","first-page":"597527","article-title":"Stage IAE follicular lymphoma of the breast: case report and review of the literature","volume":"2013","author":"Patron","year":"2013","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.ctrv.2014.05.010_b0320","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0325","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jcp.55.8.640-a","article-title":"Another case of mantle cell lymphoma presenting as breast masses","volume":"55","author":"Fadare","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0330","first-page":"181","article-title":"Primary breast mantle cell lymphoma with atypical relapse patterns","volume":"16","author":"Dane","year":"2011","journal-title":"J BUON"},{"key":"10.1016\/j.ctrv.2014.05.010_b0335","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic involvement is a common feature in mantle cell lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0340","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.05.010_b0345","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0350","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2014.05.010_b0355","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","article-title":"Limited-stage mantle-cell lymphoma","volume":"14","author":"Leitch","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0360","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/S1470-2045(12)70589-2","article-title":"Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review","volume":"14","author":"Horowitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0365","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","article-title":"A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M\/IVAC regimen for untreated Burkitt\u2019s lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAI.0b013e318266476c","article-title":"Anaplastic large cell lymphoma occurring in association with breast implants: review of pathologic and immunohistochemical features in 103 cases","volume":"21","author":"Taylor","year":"2013","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0375","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11899-013-0164-3","article-title":"Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis","volume":"8","author":"Thompson","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ctrv.2014.05.010_b0380","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/cncr.25654","article-title":"Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity","volume":"117","author":"Lechner","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0385","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3324\/haematol.2010.026237","article-title":"Effusion-associated anaplastic large cell lymphoma of the breast: time for it to be defined as a distinct clinico-pathological entity","volume":"95","author":"Thompson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2014.05.010_b0390","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/modpathol.3800266","article-title":"Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype","volume":"18","author":"Yoshida","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0395","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ijc.26352","article-title":"Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy","volume":"131","author":"Yhim","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0400","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/COC.0b013e318209aa12","article-title":"The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast","volume":"35","author":"Aviles","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0405","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/modpathol.2012.170","article-title":"T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis","volume":"26","author":"Kuper-Hommel","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CLML.2011.n.004","article-title":"Analysis of 31 cases of primary breast lymphoma: the effect of nodal involvement and microvascular density","volume":"11","author":"Zhao","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2014.05.010_b0415","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2013-10-530659","article-title":"Primary testicular lymphoma","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.05.010_b0420","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00109-012-0906-z","article-title":"Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs","volume":"90","author":"Hopken","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.ctrv.2014.05.010_b0425","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mds621","article-title":"Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study","volume":"24","author":"Holte","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0430","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood.V122.21.4353.4353","article-title":"Incorporating high-dose IV methotrexate into initial therapy results in lower rates of central nervous system (CNS) relapse in patients with high-risk diffuse large b-cell lymphoma (DLBCL)","volume":"122","author":"Cheah","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.05.010_b0435","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3324\/haematol.10892","article-title":"Rituximab and dose dense chemotherapy in primary breast lymphoma","volume":"92","author":"Aviles","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2014.05.010_b0440","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000088333","article-title":"Primary breast lymphoma: results of a controlled clinical trial","volume":"69","author":"Aviles","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2014.05.010_b0445","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0450","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3816\/CLM.2006.n.010","article-title":"Primary non-Hodgkin\u2019s lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers","volume":"6","author":"Ryan","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.ctrv.2014.05.010_b0455","first-page":"26687","article-title":"Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy","volume":"2012","author":"Campbell","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.05.010_b0460","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11899-013-0170-5","article-title":"The role of radiation therapy in the treatment of stage I-II diffuse large B-cell lymphoma","volume":"8","author":"Campbell","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.ctrv.2014.05.010_b0465","unstructured":"Non-Hodgkin\u2019s Lymphomas, version 1.2014. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): National Comprehensive Cancer Network; 2014."},{"key":"10.1016\/j.ctrv.2014.05.010_b0470","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","author":"Specht","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2014.05.010_b0475","first-page":"29","article-title":"Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy","volume":"2011","author":"Campbell","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0480","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1359-6349(09)70541-5","article-title":"Single institution preliminary experience on dose reduction to organs at risk in thoracic radiotherapy for patients enrolled in EORTC-GELA-IIL H10 study protocol on early stage Hodgkin\u2019s lymphoma","volume":"7","author":"Filippi","year":"2009","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ctrv.2014.05.010_b0485","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminhematol.2013.09.004","article-title":"Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing","volume":"50","author":"Morin","year":"2013","journal-title":"Semin Hematol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0490","first-page":"1245","article-title":"Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation","volume":"38","author":"Ashizawa","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0495","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.05.010_b0500","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.085134","article-title":"Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated elderly diffuse large B-cell lymphoma patients: phase I study by the Fondazione Italiana Linfomi","author":"Chiappella","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2014.05.010_b0505","first-page":"686","article-title":"The Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study","volume":"120","author":"Wilson","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.ctrv.2014.05.010_b0510","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.05.010_b0515","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T15:27:23Z","timestamp":1649258843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0305737214001108"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.05.010","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary breast lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}